A series of synthetic oligosaccharides based on sialyl Lewis x (sLex; and sialyl Lewis a (sLe'; Neu5Acca2-3Gall#1-31Fuca1-4jGlcNAc) was used to study the binding interactions of selectins. E-selectinimmunoglobulin fusion protein (E-selectin-Ig) bound to immobilized bovine serum albumin (BSA)-neoglycoproteins containing sLex or sLea in a Ca2"-dependent manner. Solutionphase sLex tetrasaccharide blocked this interaction by 50% at a concentration of 750±20 ,M (IC50). sLe' was more effective (IC50 = 220±20 ,uM), while nonsialylated, nonfucosylated derivatives showed little or no activity at concentrations up to 1 mM. Attachment of an 8-methoxycarbonyloctyl aglycone in a A linkage to the anomeric carbon of the GlcNAc of sLex or sLew increased their blocking activity nearly twofold. Finally, replacement of the 2-N-acetyl substituent of the GlcNAc by an azido or amino group resulted in substantial increases in activity, with the most potent inhibitor being amino substituted sLea, which was 36-fold more active (IC50 = 21±3 tM) than the reducing tetrasaccharide sLex. In contrast to results obtained with E-selectin-Ig, P-selectin-Ig binding to immobilized BSA-sLea was blocked modestly by most oligosaccharides at 1 mM, with no substantial differences among them. IC50 values of soluble oligosaccharides determined in competitive binding studies accurately predicted blocking of leukocyte adhesion to recombinant E-selectin-Ig and to cytokine-activated endothelium. (J. Clin. Invest. 1993. 91:1157-1166
Introduction
The selectin family of molecules supports adhesion of leukocytes to the blood vessel wall-a key step in the inflammatory response to injury and infection. The three known members, designated E-, P-, and L-selectin (for nomenclature summary, see reference 1 ), are structurally similar transmembrane glyco-proteins, each containing an amino-terminal lectin-like domain, an EGF repeat, and a variable number of complement regulatory-like repeats (2-7). E-selectin transcription and surface expression by vascular endothelial cells are transiently upregulated (maximal at 2-6 h) after stimulation by bacterial endotoxin and by cytokines associated with inflammation, including IL-I and TNF (2, 8) . Experiments in vitro have demonstrated that E-selectin can support the adhesion of PMN, monocytes, and a subpopulation of T lymphocytes (2, (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . P-selectin (CD62) is stored in a-granules and dense granules of platelets as well as in Weibel-Palade bodies of endothelial cells, and is rapidly (minutes) redistributed to the cell surface after activation by thrombin and other mediators (19) (20) (21) (22) (23) , where it supports leukocyte binding (24, 25) . L-selectin is present on the surface of most lymphocytes and mediates their adhesion to high endothelial venules found in peripheral lymph nodes (reviewed in references 26 and 27) . L-selectin is also found on the surface of circulating PMN and monocytes, and can support their adhesion to cytokine-activated endothelium (28) (29) (30) (31) (32) . Recent reports have suggested that the selectins are especially important in leukocyte rolling on the vessel wall, a process that can precede firm attachment and extravasation during inflammation (33) (34) (35) .
Carbohydrate recognition by selectins has been demonstrated in several studies (reviewed in reference 36). E-selectin binds sialylated, fucosylated lactosamine structures, notably sialyl-Lewis x (sLex, Neu5Aca2-3Galf1-4[Fuca [1] [2] [3] GlcNAc)' (37) (38) (39) (40) (41) . E-selectin may also bind to oligosaccharides related to sLex and sLea in which the sialic acid is replaced by a sulfate group (42) , and to fucosylated structures that lack sialic acid (43) . The pentasaccharide lacto-N-fucopentaose III (LNF-III) contains the Lewis x (Lex) determinant and was found to block the rosetting ofactivated platelets to leukocytes, a process involving P-selectin (44) . Other investigations have demonstrated that sialic acid is a component ofsome P-selectin ligands (45, 46) , and that oligosaccharides containing sLex are recognized by P-selectin (47, 48) . More recently, the recognition of the sLex structure was extended to murine L-selectin (49, 50) . Human E-and P-selectin and murine L-selectin also bind to molecules containing sLea (Neu5Aca2-3Gall 1- galactose (53) (54) (55) (56) (57) . The molecular details of selectin recognition of carbohydrates, both oligosaccharides and polysaccharides, remain to be determined.
We have examined carbohydrate binding interactions of Eand P-selectin using rationally designed synthetic oligosaccharides in three assays ofincreasing biological complexity. First, a competitive ELISA was developed to quantitate the ability of solution-phase carbohydrates to inhibit the binding ofselectinIg fusion proteins to immobilized BSA-sLex or BSA-sLea neoglycoproteins in a purified component system. Second, a cellprotein adhesion assay was used to determine the ability of soluble carbohydrates to inhibit the adhesion of cells bearing carbohydrate ligands to purified, immobilized recombinant selectin-Ig fusion proteins. Third, a cell-cell adhesion assay was employed to determine the ability of carbohydrates to inhibit the adhesion of PMN to cytokine-activated cultured human umbilical vein endothelial cells, known to express E-selectin on their surface. Our results indicate that E-and P-selectin have distinct carbohydrate recognition characteristics, and that selected modifications of the oligosaccharides sLex and sLea result in higher-affinity ligands for E-selectin. These findings suggest avenues for the development of novel anti-inflammatory therapeutic agents.
Methods

Proteins
Recombinant fusion proteins composed ofextracellular portions ofthe human selectins joined to human immunoglobulin heavy chain CH3, CH2, and hinge regions (Fig. 1, left panel) were constructed, expressed, and purified as previously described (39, 57, 58) . These soluble selectin-immunoglobulin fusion proteins (selectin-Ig) contain the signal sequence, lectin-like domain, and EGF repeat along with six, two, and two ofthe complement regulatory-like modules for E-, P-, and L-selectin-Ig, respectively. Selectin-Ig purity was assessed by SDS-PAGE followed by silver staining; protein concentration was determined using the Bradford reagent. Molecular weights used for calculation of molar concentrations are: E-selectin-Ig, 170,000; P-selectin-Ig and L-selectinIg, 120,000. BSA was protease-free grade from Boehringer-Mannheim Biochemicals, Indianapolis, IN. BSA-neoglycoproteins containing sLeX, sLea, Le[, or Lea (kindly provided by Chembiomed Ltd., Edmonton, Alberta) were made as previously described (59) . Oligosaccharides were synthesized with an aliphatic aglycone (8-methoxycarbonyloctyl; -(CH2)8CO2CH3) attached in a /3 linkage to carbon 1 of the GlcNAc (Fig. 1, right panel) 
Carbohydrates
A majority of the oligosaccharides used in these studies were provided by Chembiomed, Ltd., and were unambiguously synthesized using a chemoenzymatic route, purified by chromatographic methods with the final step on Biogel P-2, and freeze-dried in vacuo (P. V. Nikrad, M. A. Kasham, K. Wlasichuk, and A. P. Venot, Chembiomed Ltd., manuscript in preparation). In most cases, these compounds were synthesized with an aliphatic aglycone (8-methoxycarbonyloctyl; -(CH2)8-CO2CH3) attached in a 3 linkage to the reducing sugar (59, 60) (Fig. 1, right panel; Table I ). All of these compounds were pure, as assessed by 'H-nuclear magnetic resonance spectroscopy. Reducing tetrasaccha- trypan blue exclusion and the cells resuspended at a concentration of 2 X 106 cells/ml in PBS containing 0.5 mg of human serum albumin (HSA)/ml, 3 mM glucose, and 0.3 U aprotinin/ml (adhesion assay buffer). Endothelial cells. Human umbilical vein endothelial cells (Clonetics Corp., San Diego, CA) were seeded in tissue culture wells that had been coated with 0.1% gelatin in water and allowed to grow to confluence in media M 199 (Gibco Laboratories, Grand Island, NY) supplemented with 10% FCS, 5 U heparin/ml and endothelial cell growth supplement (Sigma Chemical Co.) at 15 qg/ml. Before adhesion assays, endothelial cell monolayers were washed once to remove cellular debris and activated with 200 U TNF-a/ml (gift from Biogen, Cambridge, MA) in M199 -10% FCS for 4 h at 37°C (8).
Cell-protein and cell-cell adhesion assays Results E-and P-selectin-Ig bind to immobilized BSA-sLea and BSAsLex. Soluble E-and P-selectin-Ig bound to BSA-sLea immobilized on microtiter plates in a concentration-dependent manner (Fig. 2 ). E-selectin-Ig binding appeared to depend entirely on the covalently attached oligosaccharide moiety of the neoglycoprotein, in that it failed to bind to BSA alone. Furthermore, this binding was abolished in the presence of 5 mM EGTA, consistent with the function of E-selectin as a C-type lectin (62) . In similar studies, E-selectin-Ig bound to immobilized BSA-sLex in a concentration-and Ca2 -dependent fashion, but displayed very little binding to BSA-neoglycoproteins containing Lea or Lex (at 100 nM E-selectin-Ig, -6 and < 2 mOD450/min, respectively). P-selectin also bound to immobilized BSA-sLea ( Fig. 2) and BSA-sLex (not shown) in a concentration-dependent manner. Unlike E-selectin-Ig, P-selectin-Ig showed a small amount of binding to immobilized BSA that had not been derivatized with oligosaccharide. In a typical ELISA, 100 nM P-selectin-Ig binding to BSA alone gave a signal of 9 mOD450/ min., whereas the same concentration of E-selectin-Ig produced a BSA signal of 3 mOD450/min (background signal in the absence of selectin-Ig was 2-4 mOD450/ min). This P-selectin-Ig binding to unconjugated BSA was apparently unrelated to a Ca2 -dependent lectin activity since it was enhanced severalfold in the presence of EGTA. With this high background binding to BSA subtracted, the binding ofP-selectin-Ig to BSAsLea ( Fig. 2) and BSA-sLex was largely blocked by 5 Table I ) blocked specific binding by more than 50%, with sLea exhibiting higher activity than sLex (Fig. 3) . The non-sialylated trisaccharide Lex showed no blocking activity at this concentration, while Lea demonstrated slight activity ( 13-20% inhibition, four experiments). The ability ofsolution-phase tetrasaccharides sLea and sLeX to block binding of E-selectin-Ig to immobilized BSA-neoglycoproteins was interpreted as competitive inhibition.
To determine structural requirements for carbohydrate recognition by E-selectin, we tested a variety ofsynthetic oligosaccharides with modifications of the sialic acid and/or fucose groups. The importance of the linkage of sialic acid to the saccharide backbone was demonstrated using an isomer of sLea, designated 2-6sLea, in which the sialic acid is attached to galactose in an a2-6 rather than an a2-3 linkage. This carbohydrate displayed no significant blocking activity at a concentration of 500 uM. Two additional modifications to the sialic acid of sLex, namely attachment of an amino group on carbon 9 (9NH2sLeX) or replacement of the N-acetyl group at carbon 5 by a hydroxyl group (KDNLeX), resulted in compounds that had less activity than unmodified sLex.
The importance of fucose position and linkage in sLea and sLeX was examined using selected oligosaccharides (Fig. 3) . sLex-and sLea-related trisaccharides that lack fucose, namely sLacNAc (Neu5Aca2-3Galfl1-4GlcNAc -OR') and sLec (Neu5Aca2-3Galf1l-3GlcNAcf-OR') respectively, had no blockina activitv. In addition. Fuc1-6sLacNAc. a comnnound reducing sugar (Table I ). The presence of this aglycone was r E-selectin. The adfound to measurably enhance the blocking activity of sLea and mono-and oligosacof sLex (Fig. 4) tives of sLea and sLex (Fig. 6, bottom) . It is noteworthy that among solution-phase oligosaccharide inhibitors of P-selectinIg, both nonsialylated and sialylated structures had some blocking activity, with the latter being moderately more effective. As noted above, however, P-selectin-Ig exhibited a substantially higher level ofbinding to immobilized BSA-sLex and BSA-sLea than to their nonsialylated counterparts BSA-Lex and BSA-Lea. In separate experiments, both heparin (a glycosaminoglycan composed ofalternating, sulfated residues ofglucosamine and uronic acid) and fucoidan (a homopolymer of sulfated L-fucose) blocked the binding of P-selectin-Ig to BSAsLe' but had no effect on E-selectin-Ig binding (Fig. 7) . Blocking ofcell adhesion by oligosaccharides in vitro. Results ofcompetitive binding studies described above accurately predicted relative effects of solution-phase carbohydrates on leukocyte adhesion to purified selectin-Ig fusion proteins and to cytokine-activated endothelial monolayers. At a concentration of 1 mM, sLex blocked adhesion of PMN to immobilized recombinant E-selectin-Ig by -50% (Fig. 8) . sLex showed little or no blocking of PMN adhesion at concentrations up to 1 mM, a result consistent with its IC50 being threefold higher than that of sLea in the competitive binding ELISA (Table II) . In further agreement with the competitive binding results, the ability of oligosaccharides to block cell adhesion to E-selectinIg required sialic acid linked a2-3 to galactose, and fucose linked to the GlcNAc. Compounds with sialic acid linked a2-6 to galactose as well as compounds lacking sialic acid or fucose failed to block PMN adhesion at concentrations up to 1 mM (data not shown). Further, sLea(GlcN3) and sLea(GlcNH2) were much more active than sLea in blocking the adhesion of PMN to E-selectin-Ig. sLea(GlcNHPr), which has an N-propionyl group substituted for the N-acetyl group of GlcNAc, failed to block adhesion at a concentration of 1 mM (Fig. 8) . In separate experiments, PMN adhesion to immobilized P-selectin-Ig was poorly blocked by soluble oligosaccharides related to sLex and sLea (not shown). Although several oligosaccharides Table I and Fig. 1 .
(including nonsialylated and nonfucosylated structures) blocked PMN adhesion to P-selectin-Ig in certain assays, the effect was modest (typically < 30% inhibition) and inconsistent. Neither azido nor amino substitutions at carbon 2 of GlcNAc enhanced the ability ofthe compounds to block leukocyte adhesion to P-selectin-Ig. In a more complex adhesion assay, we examined the effects of solution-phase oligosaccharides on the adhesion of PMN to human umbilical vein endothelial cell mdnolayers. Cytokine activated endothelial cells express E-selectin in abundance, and thereby support leukocyte adhesion (8) . As shown in Fig. 9 , sLea at a concentration of 1 mM partially blocked PMN adhesion. sLea(GlcNH2) was the most active blocker in this system, followed by sLea(GlcN3). Moreover, sLeX was consistently less active than sLea in blocking PMN adhesion to activated endothelial cell monolayers, typically blocking 0-30% of adhesion. Oligosaccharide inhibition data from the three assays were in 1162 Nelson et al. 21±3 (4) the oligosaccharide sLea, found on colon cancer cells, is bound by E-selectin (39, 68, 69) . Recent reports demonstrate that human P-selectin and murine L-selectin can also bind carbohydrates bearing sLex and sLea (47, 49, 50, 53) . Studies on selectin recognition ofoligosaccharides have been paralleled by investigations suggesting that certain proteins contribute to cellular ligands of L-and P-selectin. For example, immobilized L-selectin has been used to affinity purify from murine lymph nodes a 50-kD sulfated, fucosylated, and sialylated glycoprotein, as well as a related 90-kD glycoprotein (70) . Molecular cloning of the 50-kD glycoprotein revealed a heavily glycosylated mucin-type molecule containing two serine/threonine rich domains (71 ) . Separate studies have revealed that P-selectin binds a small number of protease-sensitive sites on PMN and HL60 cells (46) . Further, P-selectin has been used to affinity purify and ligand blot a glycoprotein(s) from leukocyte extracts, with an apparent M, on polyacrylamide gels of -250,000 under nonreducing conditions and 120,000 under reducing conditions (72) . Together these studies suggest that both P-and L-selectin bind with high affinity to a relatively small number ofcell surface glycoproteins. The function ofthe protein in these ligands remains to be determined.
Our approach has been to use synthetic oligosaccharides related to sLex and sLea to determine fine specificity of selectin recognition and to identify high-affinity ligands for potential use as antiinflammatory therapeutic agents. Toward this end, we have emphasized the measurement of binding interactions between purified macromolecules and their inhibition by solution-phase oligosaccharides. Moreover, we have chosen to focus on oligosaccharides that show inhibitory activity at concentrations < 1 mM. Our observations support the hypothesis that E-selectin binding to sLea and sLex involves the sialic acid, galactose, and fucose residues, in agreement with previous reports (51, 52) . First, nonsialylated and nonfucosylated oligosaccharides corresponding to both sLea and sLex had little or no effect on E-selectin interactions at concentrations up to 1 mM. Second, E-selectin failed to recognize a structural isomer of sLea (2-6sLea) with the sialic acid linked a2-6 (rather than a2-3) to galactose. Finally, a trisaccharide similar to sLex (Fucl-6sLacNAc) with fucose linked a 1-6 (rather than a 1-4) had little or no activity in our assays. Our studies also point to the importance of the N-acetyl group at carbon 5 of Neu5Ac because the oligosaccharide KDNLex, which contains a different type of sialic acid lacking this group (KDN = keto-deoxynonulosonic acid; for review of sialic acid diversity, see reference 73), was significantly less active in E-selectin assays than sLex.
Prior reports (51, 52) have presented conflicting data on the relative activities of sLeX and sLea determinants in cell adhesion assays; we note that using either soluble reducing tetrasaccharides or 8-methoxycarbonyloctyl glycosides, sLea was the more potent blocker of E-selectin-Ig binding (by approximately threefold) and of E-selectin-dependent adhesion. Furthermore, we have demonstrated that replacement of the Nacetyl (-NHCOCH3) group of sLex or sLea with amino (-NH2) or azido (-N3) moieties enhances their interaction with E-selectin by an additional four-to sixfold in the competitive ELISA (Table II) . In contrast, replacement ofthe N-acetyl group with an N-propionyl group (-NHCOCH2CH3) decreased the blocking activity of sLea and had little or no effect on sLex (Fig. 5) . It has been reported that a tetrasaccharide related to sLex with glucose in place of GlcNAc is a better inhibitor than sLex of E-selectin-dependent adhesion (52) and of E-selectin-Ig binding to immobilized sLex glycolipid (49) . Taken Leukocyte adhesion to the vessel wall and extravasation are essential for host defense. However, in certain settings such as adult respiratory distress syndrome, ischemic reperfusion injury, and arthritis, leukocytes cause substantial tissue damage. The importance ofE-selectin in leukocyte adhesion and inflammation is now widely accepted. In an effort to identify anti-inflammatory therapeutic agents we have chosen to focus on soluble oligosaccharides related to sLex, the first described ligand for E-selectin. We have demonstrated that solution-phase sLea is a more potent blocker of E-selectin than is sLex. Furthermore, addition ofan aliphatic aglycone in combination with an amino substitution on the GlcNAc of sLea resulted in a compound with 36-fold higher activity than sLex, as measured in a competitive binding assay. These studies have also demonstrated differential recognition of oligosaccharides by E-and P-selectin. It is anticipated that high-affinity carbohydrate ligands for E-selectin may prove useful in the treatment of human diseases.
